Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.
This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) 2017 Report focuses primarily on the revised and novel parts of the document. The most significant changes include: 1) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; 2) for each of the groups A to D, escalation strategies for pharmacological treatments are proposed; 3) the concept of de-escalation of therapy is introduced in the treatment assessment scheme; 4) nonpharmacologic therapies are comprehensively presented and; 5) the importance of comorbid conditions in managing COPD is reviewed.
University of Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany claus.vogelmeier@med.uni-marburg.de.|These authors contributed equally to the manuscript.
Claus F
CF
Vogelmeier
Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.|These authors contributed equally to the manuscript.
Gerard J
GJ
Criner
New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA.|These authors contributed equally to the manuscript.
Fernando J
FJ
Martinez
University of Texas Health Science Center and South Texas Veterans Health Care System, San Antonio, TX, USA.
Antonio
A
Anzueto
National Heart and Lung Institute, Imperial College, London, UK.
Peter J
PJ
Barnes
McGill University Health Centre, McGill University, Montreal, Canada.
Jean
J
Bourbeau
Brigham and Women's Hospital, Boston, MA, USA.
Bartolome R
BR
Celli
State Key Lab for Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Rongchang
R
Chen
University of Leuven, Leuven, Belgium.
Marc
M
Decramer
University of Modena and Reggio Emilia, Modena, Italy.
Leonardo M
LM
Fabbri
Flinders University Faculty of Medicine, Bedford Park, Australia.
Peter
P
Frith
Royal Devon and Exeter Hospital, Exeter, UK.
David M G
DM
Halpin
Universidad de la República, Hospital Maciel, Montevideo, Uruguay.
M Victorina
MV
López Varela
Hokkaido University School of Medicine, Sapporo, Japan.
Masaharu
M
Nishimura
Hôpital Cochin (APHP), University Paris Descartes, Paris, France.
Nicolas
N
Roche
Thorax Institute, Hospital Clinic Universitat de Barcelona, Barcelona, Spain.
Roberto
R
Rodriguez-Roisin
St Paul's Hospital, University of British Columbia, Vancouver, Canada.
Don D
DD
Sin
University of Manchester, Manchester, UK.
Dave
D
Singh
University Hospital, Birmingham, UK.
Robert
R
Stockley
University of Manchester, Manchester, UK.
Jørgen
J
Vestbo
National Heart and Lung Institute, Imperial College, London, UK.
Jadwiga A
JA
Wedzicha
Hospital Clínic, Universitat de Barcelona, Ciberes, Barcelona, Spain.
Alvar
A
Agusti
D001993:Bronchodilator Agents / Q000627:therapeutic use; D015897:Comorbidity; D019468:Disease Management; D018450:Disease Progression; D014943:Global Health; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis* / Q000517:prevention & control* / Q000628:therapy*; D012307:Risk Factors; D012720:Severity of Illness Index; D013147:Spirometry; D063189:Symptom Assessment
D001993:Bronchodilator Agents